
|Videos|August 16, 2017
Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?
Author(s)Contagion Editorial Staff
Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.
Advertisement
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, breaks down the process of how Staphylococcus aureus (S. aureus) is able to gain resistance to methicillin. Dr. Pilch also explains if the pathogen can gain resistance to a new prodrug he helped develop: TXA709.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Oral Carbapenem Tebipenem HBr Demonstrates Non-Inferiority to IV Therapy in Phase III PIVOT-PO Trial
2
Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections
3
New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine
4
Lori Handy, MD, MSCE, Discusses New Era of Dynamic, Trust-Based Health Communication
5